JP2024521105A5 - - Google Patents
Info
- Publication number
- JP2024521105A5 JP2024521105A5 JP2023571866A JP2023571866A JP2024521105A5 JP 2024521105 A5 JP2024521105 A5 JP 2024521105A5 JP 2023571866 A JP2023571866 A JP 2023571866A JP 2023571866 A JP2023571866 A JP 2023571866A JP 2024521105 A5 JP2024521105 A5 JP 2024521105A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- antibody
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163192217P | 2021-05-24 | 2021-05-24 | |
| US63/192,217 | 2021-05-24 | ||
| PCT/EP2022/064061 WO2022248478A1 (en) | 2021-05-24 | 2022-05-24 | Compositions and methods for treating lung cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024521105A JP2024521105A (ja) | 2024-05-28 |
| JP2024521105A5 true JP2024521105A5 (https=) | 2025-06-03 |
Family
ID=82100132
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023571866A Pending JP2024521105A (ja) | 2021-05-24 | 2022-05-24 | 肺癌の処置用組成物及び方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240254235A1 (https=) |
| EP (1) | EP4347038A1 (https=) |
| JP (1) | JP2024521105A (https=) |
| KR (1) | KR20240012413A (https=) |
| CN (1) | CN117425493A (https=) |
| AU (1) | AU2022281992A1 (https=) |
| BR (1) | BR112023023833A2 (https=) |
| CA (1) | CA3219960A1 (https=) |
| IL (1) | IL308530A (https=) |
| TW (1) | TW202313107A (https=) |
| WO (1) | WO2022248478A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2025529196A (ja) * | 2022-09-01 | 2025-09-04 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 間葉系上皮転換因子（ｍｅｔ）標的薬を使用して非小細胞肺がんを治療する方法 |
| TW202504636A (zh) * | 2023-04-14 | 2025-02-01 | 瑞典商阿斯特捷利康公司 | 非小細胞肺癌的治療 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2504364T3 (pl) | 2009-11-24 | 2017-12-29 | Medimmune Limited | Ukierunkowane środki wiążące przeciwko B7-H1 |
| US20190276543A1 (en) * | 2018-03-08 | 2019-09-12 | Astrazeneca Pharmaceuticals Lp | Compositions and methods for treating late stage lung cancer |
| JP2023524270A (ja) * | 2020-05-04 | 2023-06-09 | メルク・シャープ・アンド・ドーム・エルエルシー | Ｐｄ－１アンタゴニスト、化学放射線療法およびｐａｒｐ阻害剤の組み合わせを用いた癌の治療方法 |
-
2022
- 2022-05-24 EP EP22731132.1A patent/EP4347038A1/en active Pending
- 2022-05-24 KR KR1020237041378A patent/KR20240012413A/ko active Pending
- 2022-05-24 JP JP2023571866A patent/JP2024521105A/ja active Pending
- 2022-05-24 TW TW111119315A patent/TW202313107A/zh unknown
- 2022-05-24 BR BR112023023833A patent/BR112023023833A2/pt not_active Application Discontinuation
- 2022-05-24 CN CN202280037041.0A patent/CN117425493A/zh active Pending
- 2022-05-24 WO PCT/EP2022/064061 patent/WO2022248478A1/en not_active Ceased
- 2022-05-24 IL IL308530A patent/IL308530A/en unknown
- 2022-05-24 AU AU2022281992A patent/AU2022281992A1/en not_active Abandoned
- 2022-05-24 US US18/560,527 patent/US20240254235A1/en active Pending
- 2022-05-24 CA CA3219960A patent/CA3219960A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111065411B (zh) | Pd-1抗体和vegfr抑制剂联合治疗小细胞肺癌的用途 | |
| AU2001295002B2 (en) | Treatment of hyperproliferative diseases with epidermal growth factor receptor antagonists | |
| JP2023551559A5 (https=) | ||
| CN113613674A (zh) | 治疗小细胞肺癌的联用药物组合物 | |
| JP2022543062A5 (https=) | ||
| JP2024521105A5 (https=) | ||
| CN118267469A (zh) | 治疗驱动基因阳性肺癌的联用药物组合物 | |
| WO2023061472A1 (zh) | 抗her2抗体药物偶联物和酪氨酸激酶抑制剂联合在制备治疗肿瘤的药物中的用途 | |
| TW202346342A (zh) | 抗tim-3抗體與抗pd-1抗體的藥物組合 | |
| TWI870592B (zh) | 使用免疫檢查點抑制劑抗體治療癌症之方法和組合 | |
| WO2020233602A1 (zh) | 用于联合治疗小细胞肺癌的喹啉衍生物 | |
| JP2021530502A5 (https=) | ||
| JP2023524359A5 (https=) | ||
| JP2022547061A5 (https=) | ||
| JP2021523096A5 (https=) | ||
| TW200306185A (en) | Combinations comprising EPOTHILONES and anti-metabolites | |
| WO2021213523A1 (zh) | 抗pd-1抗体和抗ctla-4抗体的组合在预防或治疗癌症中的用途 | |
| JP2023500480A5 (https=) | ||
| JP2022549218A5 (https=) | ||
| JP2025526402A5 (https=) | ||
| CN119894516A (zh) | 用于治疗晚期实体瘤的组合物和方法 | |
| JP2021528399A5 (https=) | ||
| JP2024503379A5 (https=) | ||
| CN110013552B (zh) | 抗pd-1抗体、吉西他滨和铂类药物联合治疗恶性胆道肿瘤的用途 | |
| JP2024526742A5 (https=) |